Abstract: The invention provides ?-helix mimetic structures and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the treatment of diseases including fibrosis, such as pulmonary fibrosis.

Abstract: The invention provides ?-helix mimetic structures and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the treatment of diseases including fibrosis, such as pulmonary fibrosis.

Abstract: The invention provides ?-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R1 and R2 as set out in the description and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the treatment of diseases including fibrosis, such as pulmonary fibrosis.

Abstract: The invention provides ?-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R1 and R2 as set out in the description and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the treatment of diseases including fibrosis, such as pulmonary fibrosis.

Abstract: The invention provides ?-mimetic structure of formula (I), wherein A is —(C?O)—(CHR3)— or —(C?O)—; B is —(NR5)— or —(CHR6)—; D is —(C?O)—(CHR7)— or —(C?O)—; E is -(ZR8)— or —(C?O)—, where Z is nitrogen or CH; —(XR9)n—, —(CHR10)—(NR6)—, —(C?O)—(XR12)—, —(C?N—W—R1)—, —(C?O)—, —(X—(C?O)—R13)—, —(X—(C?O)—NR13R14)—, —(X—(SO2)—R13)—, or —(X—(C?O)—OR13)—, where X is nitrogen or CH, and n=0 or 1; W is —Y(C?O)—, —(C?O)—(NH)—, —(SO2)—, —(CHR14)—, —(C?O)—(NR15)—, substituted or unsubstituted oxadiazole, substituted or unsubstituted triazole, substituted or unsubstituted thiadiazole, substituted or unsubstituted 4,5-dihydrooxazole, substituted or unsubstituted 4,5-dihydrothiazole, substituted or unsubstituted 4,5-dihydroimidizole, or nothing, where Y is oxygen or sulfur; and R1, R2, R3, R4, R5, R6, R7, R8, R9 R10, R11, R12, R13, R14, and R15 are the same or different and independently selected from an amino acid side chain moiety or derivative thereof, the remainder of the molecule, a linker and a solid support, and ster

Abstract: The invention provides ?-mimetic structure of formula (I), wherein A is —(C?O)—(CHR3)— or —(C?O)—; B is —(NR5)— or —(CHR6)—; D is —(C?O)—(CHR7)— or —(C?O)—; E is -(ZR8)— or —(C?O)—, where Z is nitrogen or CH; —(XR9)n—, —(CHR10)—(NR6)—, —(C?O)—(XR12)—, —(C?N—W—R1)—, —(C?O)—, —(X—(C?O)—R13)—, —(X—(C?O)—NR13R14)—, —(X—(SO2)—R13)—, or —(X—(C?O)—OR13)—, where X is nitrogen or CH, and n=0 or 1; W is —Y(C?O)—, —(C?O)—(NH)—, —(SO2)—, —(CHR14)—, —(C?O)—(NR15)—, substituted or unsubstituted oxadiazole, substituted or unsubstituted triazole, substituted or unsubstituted thiadiazole, substituted or unsubstituted 4,5-dihydrooxazole, substituted or unsubstituted 4,5-dihydrothiazole, substituted or unsubstituted 4,5-dihydroimidazole, or nothing, where Y is oxygen or sulfur; and R1, R2, R3, R4, R5, R6, R7, R8, R9 R10, R11, R12, R13, R14, and R15 are the same or different and independently selected from an amino acid side chain moiety or derivative thereof, the remainder of the molecule, a linker and a solid support, and ster

Abstract: The invention provides ?-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R1 and R2 as set out in the description and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the treatment of fibrotic diseases, such as pulmonary fibrosis.

Abstract: The invention provides ?-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R1 and R2 as set out in the description and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate to the reversal of fibrotic conditions, such as pulmonary fibrosis.

Abstract: Methods and agents are disclosed for modulating the interaction of ?-catenin or ?-catenin with CBP or p300. Agents that increase the binding of CBP to ?-catenin are associated with enhancing the ?-catenin-related proliferation of adult stem cells, including hematopoietic stem cells, neural stem cells, skin stem cells, and pancreatic stem cells, as well as embryonic stem cells.